Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis

Basit Öğe Kaydı
dc.contributor.authorYazgan, Serpil
dc.contributor.authorÇelik, Uğur
dc.contributor.authorIşık, Metin
dc.contributor.authorKarahan Yeşil, Nesibe
dc.contributor.authorBaki, Ali Erdem
dc.contributor.authorŞahin, Hatice
dc.contributor.authorGencer, Ercan
dc.contributor.authorDoğan, İsmail
dc.date.accessioned2019-05-10T09:39:35Z
dc.date.available2019-05-10T09:39:35Z
dc.date.issued2017
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractTo evaluate the efficacy of golimumab on severe and frequent recurrent anterior uveitis in patients with HLA-B27-positive ankylosing spondylitis. In this study, 15 eyes of 12 HLA-B27-positive AS patients with resistant anterior uveitis who received 50 mg of subcutaneous golimumab (Gol) per month due to frequent uveitis recurrences were analyzed retrospectively between May 2013 and October 2015. Assessment criteria were uveitis activity, the number of recurrence of uveitis, visual acuity, systemic corticosteroid, or other drug requirement for maintenance of remission of AU. Twelve patients (15 eyes) with HLA-B27-positive ankylosing spondylitis and anterior uveitis have been treated with golimumab 50 mg/month. Remission of uveitis was observed in 12 eyes out of 15. Malign hypertension developed in one subject after the second dose of golimumab therefore the treatment was stopped and this subject was excluded from the study. Median follow-up time was 11 months (interquartile range: 8–18). No uveitic reaction was seen except in the patient who stopped treatment. No topical or systemic steroid necessity was needed except in two cases with oral 4 mg systemic maintenance. Visual acuity was significantly increased (p = 0.002). Golimumab may be a new and effective choice for maintaining remission and the prevention of recurrences of severe, resistant anterior uveitis in patients with HLA-B27-positive ankylosing spondylitis. © 2016, Springer Science+Business Media Dordrecht.
dc.identifier.citationYazgan, S., Celik, U., Işık, M., Yeşil, N. K., Baki, A. E., Şahin, H., ... & Doğan, İ. (2017). Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. International ophthalmology, 37(1), 139-145.
dc.identifier.doi10.1007/s10792-016-0239-y
dc.identifier.endpage145en_US
dc.identifier.issn0165-5701
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ2
dc.identifier.startpage139en_US
dc.identifier.urihttps://doi.org/10.1007/s10792-016-0239-y
dc.identifier.urihttps://hdl.handle.net/11491/734
dc.identifier.volume37en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSpringer Netherlands
dc.relation.ispartofInternational Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAnterior Uveitisen_US
dc.subjectGolimumaben_US
dc.subjectHLA-B27- Positive Ankylosing Spondylitisen_US
dc.titleEfficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu